PDCD1 and head and neck squamous cell carcinoma: Immune checkpoint blockade (ICB) of programmed cell death protein 1 (PD-1) therapy nearly triples the 2-year overall survival rate compared to investigator’s choice in platinum-refractory, recurrent, or metastatic HNSCC patients [5,6].